Holen Sie sich die Stockscreener-App
207.94
2.10%
-4.46
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$212.40
Offen:
$213.55
24-Stunden-Volumen:
4.61M
Relative Volume:
0.64
Marktkapitalisierung:
$367.80B
Einnahmen:
$61.16B
Nettoeinkommen (Verlust:
$4.19B
KGV:
88.06
EPS:
2.3614
Netto-Cashflow:
$17.82B
1W Leistung:
-0.43%
1M Leistung:
-8.40%
6M Leistung:
-9.79%
1J Leistung:
+19.37%
1-Tages-Spanne:
$207.75
$214.10
1-Wochen-Bereich:
$201.66
$214.10
52-Wochen-Spanne:
$168.54
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Haisco Pharmaceutical Signs Licensing Agreement With AbbVie Group - TradingView — Track All Markets
AbbVie stock price forecast: sellers in control as ABBV fails to hold above support - Traders Union
Massachusetts Financial Firm Trims Stake in AbbVie - National Today
-2.05% for AbbVie stock as renewed selling keeps shares below key resistance - Traders Union
Factory Mutual Insurance Co. Decreases AbbVie Stock Position - National Today
AbbVie (ABBV) Receives a Buy from RBC Capital - The Globe and Mail
CapEx per share of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Sector Update: Health Care - Moomoo
3 Companies Aggressively Raising Dividends While Others Play Defense - Investing.com
RBC Capital reiterates Abbvie stock Outperform rating at $260 target - Investing.com
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer? - Yahoo Finance
Night Vision Disturbances Pipeline 2026: MOA, ROA, - openPR.com
AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says - Moomoo
Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating - marketscreener.com
Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more (AGNC:NASDAQ) - Seeking Alpha
Guggenheim raises Abbvie stock price target to $249 on immunology By Investing.com - Investing.com Canada
Daner Wealth Management, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
BNY Mellon Worldwide Growth Fund, Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Sues Over 340B Patient Definition In Chicago Area - Hoodline
AbbVie: Fairly Valued And Positioned For Growth (NYSE:ABBV) - Seeking Alpha
Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead - Yahoo Finance
ABBV Stock Quote Price and Forecast - CNN
Is AbbVie (ABBV) Still Attractive After Recent Pullback And Mixed Valuation Signals - simplywall.st
TrumpRx adds more drugs as AbbVie, Genentech join self-pay platform - TechTarget
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV) - Seeking Alpha
AbbVie wades into drug discount fight, suing feds over provider audits - Crain's Chicago Business
AbbVie challenges 340B patient definition in US court - The Pharma Letter
Exclusive: AbbVie sues to narrow drug discount patient definition - Axios
Lobbying Update: $80,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie Dividend Growth & Portfolio Outlook 2026News and Statistics - IndexBox
AbbVie Says 340B Program Defines 'Patient' Too Broadly - Law360
AbbVie files lawsuit to address 'outdated' drug discount eligibility program - Reuters
AbbVie Sue US Over ‘Patient’ Definition Under Drug Discount Plan - Bloomberg Law News
Buying pressure lifts AbbVie stock higher in today's trading - Traders Union
AbbVie sues to narrow 340B eligibility - FirstWord Pharma
AbbVie (ABBV) Challenges Government's Drug Discount Program Defi - GuruFocus
AbbVie : moves to close loopholes and strengthen accountability in 340B program - marketscreener.com
Abbvie Files Lawsuit To Address 340B Program Guidance - TradingView
AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal (NYSE:ABBV) - Seeking Alpha
ABBV: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Cantor Fitzgerald lowers Abbvie stock price target on valuation - Investing.com
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year - AbbVie News Center
$20,000 grants return as BOTOX reopens program for 250 women - Stock Titan
AbbVie Stock Review 2026: Earnings Outlook, Dividend Yield, and ValuationNews and Statistics - IndexBox
Ethos Capital Buys Stake in AbbVie - National Today
Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story? - Yahoo Finance
AbbVie: Lowered Guidance Is Just NoiseReiterate Buy - Seeking Alpha
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges - Intellectia AI
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade - Yahoo Finance
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):